Previous 10 | Next 10 |
Celldex (NASDAQ: CLDX ): Q3 GAAP EPS of -$0.75 beats by $0.09 . More news on: Celldex Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HAMPTON, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2019. “Celldex achieved a significant milestone last week, reporting data at SITC that CDX-1140 has ...
-CDX-0159 IND accepted; Phase 1 study to start by YE 2019- -CDX-527 on track for IND filing in 1H 2020- HAMPTON, N.J., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data from the Company’s preclinical pipeline this weekend. A review...
-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study- -Expansion cohort in head and neck squamous cell carcinoma added based on observed clinical activity- -Clinical trial collaboration with Merck announced to evaluate CDX-1140 with KEYTRUDA®- HAMPTON,...
HAMPTON, N.J., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and scientific conferences. Society for Immunotherapy of Cancer (SITC) 34th An...
HAMPTON, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Tibor Keler, PhD, Cofounder, Executive Vice President and Chief Scientific Officer, will present a corporat...
Celldex Therapeutics, Inc. (CLDX) Q2 2019 Results Earnings Conference Call August 8, 2019, 04:30 PM ET Company Participants Sarah Cavanaugh - Senior Vice President, Corporate Affairs and Administration Anthony Marucci - Founder, President and Chief Executive Officer Margo Heath-C...
Celldex (NASDAQ: CLDX ): Q2 GAAP EPS of -$0.84 beats by $0.33 . Revenue of $0.7M (-74.6% Y/Y) misses by $0.56M . Cash and equivalents of $81.3M. Press Release More news on: Celldex Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
HAMPTON, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2019. The Company will host a conference call at 4:30 p.m. ET today to provide an update on its pipeline and upcom...
HAMPTON, N.J., July 31, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2019 financial results on Wednesday, August 7, 2019 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...